Viking's Obesity Trials Fully Enrolled, Oral VK2735 Phase 3 Set for Q4
VKTX sits 45% above its 52-week low of $22.959.
Summary
Viking Therapeutics reported Q2 2026 results with a strong cash position of $502 million and a milder-than-expected net loss. The Phase 3 VANQUISH 1 and 2 trials for subcutaneous VK2735 are fully enrolled and advancing, with top-line data expected to be a major catalyst. Oral VK2735 Phase 3 initiation is planned for Q4 2026, positioning it as a potential first-in-class oral dual GLP-1/GIP agonist. Maintenance dosing data for VK2735 is due this quarter, which could differentiate the drug for long-term weight management. The company also initiated a Phase 1 trial for amylin agonist VK3019 and appointed a new chief medical officer, signaling infrastructure build-out. This follows a prior 8-K disclosing a dispute with Ligand over VK2809, but the obesity pipeline remains the primary value driver.
Updates
· Wiseek News — Canaccord raised its price target to $114 from $107.
At the time of this announcement, VKTX was trading at $33.27 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.9B. The 52-week trading range was $22.96 to $43.15. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: PR Newswire.